Femasys (NASDAQ:FEMY) Trading Down 2.4% – Should You Sell?

Femasys Inc. (NASDAQ:FEMY) shares fell 2.4% on Monday . The company traded as low as $0.3610 and last traded at $0.3779. 837,438 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 2,021,601 shares. The stock had previously closed at $0.3870.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on FEMY. Wall Street Zen lowered shares of Femasys from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Lake Street Capital initiated coverage on shares of Femasys in a research report on Tuesday, March 3rd. They set a “buy” rating and a $1.50 target price for the company. Finally, Weiss Ratings lowered shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 18th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.33.

Femasys Trading Down 2.4%

The company has a market cap of $22.82 million, a PE ratio of -1.40 and a beta of -2.23. The stock’s 50 day moving average is $0.41 and its 200-day moving average is $0.58. The company has a quick ratio of 1.98, a current ratio of 3.91 and a debt-to-equity ratio of 0.53.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Friday, May 8th. The company reported $0.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.07. Femasys had a negative net margin of 521.97% and a negative return on equity of 258.08%. The company had revenue of $0.42 million for the quarter, compared to the consensus estimate of $0.77 million.

Institutional Investors Weigh In On Femasys

Several hedge funds and other institutional investors have recently made changes to their positions in FEMY. Kovack Advisors Inc. purchased a new stake in shares of Femasys in the fourth quarter valued at $27,000. HRT Financial LP purchased a new stake in shares of Femasys in the fourth quarter valued at $30,000. Cetera Investment Advisers purchased a new stake in shares of Femasys in the fourth quarter valued at $36,000. Osaic Holdings Inc. purchased a new stake in shares of Femasys in the second quarter valued at $45,000. Finally, State Street Corp raised its stake in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares during the period. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.